These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32852696)

  • 1. Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency.
    Raji A; Xu ZJ; Lam RLH; O'Neill EA; Kaufman KD; Engel SS
    Diabetes Ther; 2020 Oct; 11(10):2419-2428. PubMed ID: 32852696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study.
    Scott R; Morgan J; Zimmer Z; Lam RLH; O'Neill EA; Kaufman KD; Engel SS; Raji A
    Diabetes Obes Metab; 2018 Dec; 20(12):2876-2884. PubMed ID: 30019498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naïve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial.
    Ito D; Inoue K; Saito D; Hamaguchi K; Kaneko K; Sumita T; Inukai K; Inoue I; Shimada A
    Diabetes Ther; 2021 Dec; 12(12):3201-3215. PubMed ID: 34709582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of treatment with sitagliptin or sulfonylurea in patients with type 2 diabetes mellitus and mild renal impairment: a post hoc analysis of clinical trials.
    Ommen ES; Xu L; O'Neill EA; Goldstein BJ; Kaufman KD; Engel SS
    Diabetes Ther; 2015 Mar; 6(1):29-40. PubMed ID: 25633134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective Observational Study on Assessing Sitagliptin and Dapagliflozin as a Fixed-Dose Combination in the Indian Population With Type 2 Diabetes Mellitus: The SIDAXA Study.
    Chawla M; Panneerselvam D; Gundgurthy A; Sud S; Alamchandani R; Aneja P; Nair R; Korukonda KR
    Cureus; 2024 May; 16(5):e60815. PubMed ID: 38910691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Real DAPSI: A Real-World Retrospective Study on Assessing the Efficacy and Safety of a Fixed-Dose Combination of Dapagliflozin and Sitagliptin in the Indian Population.
    Bhattacharjee R; Rai M; Joshi P; Prasad A; Birla A
    Cureus; 2023 Oct; 15(10):e46767. PubMed ID: 37954782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
    Dharmalingam M; Aravind SR; Thacker H; Paramesh S; Mohan B; Chawla M; Asirvatham A; Goyal R; Shembalkar J; Balamurugan R; Kadam P; Alva H; Kodgule R; Tandon M; Vaidyanathan S; Pendse A; Gaikwad R; Katare S; Suryawanshi S; Barkate H
    Drugs; 2020 Apr; 80(6):587-600. PubMed ID: 32162274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease.
    Guja C; Frías JP; Suchower L; Hardy E; Marr G; Sjöström CD; Jabbour SA
    Diabetes Ther; 2020 Jul; 11(7):1467-1480. PubMed ID: 32306296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
    Peng XV; Marcinak JF; Raanan MG; Cao C
    Diabetes Obes Metab; 2017 Aug; 19(8):1127-1134. PubMed ID: 28239939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea.
    Han E; Kim A; Lee SJ; Kim JY; Kim JH; Lee WJ; Lee BW
    Diabetes Ther; 2018 Aug; 9(4):1689-1701. PubMed ID: 29998370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
    Ku EJ; Lee DH; Jeon HJ; Oh TK
    Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
    Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
    Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naïve patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre, randomized, 104-week, open-label, active-controlled trial.
    Kim NH; Moon JS; Lee YH; Cho HC; Kwak SH; Lim S; Moon MK; Kim DL; Kim TH; Ko E; Lee J; Kim SG
    Diabetes Obes Metab; 2024 Jun; ():. PubMed ID: 38853720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study.
    Miller S; Krumins T; Zhou H; Huyck S; Johnson J; Golm G; Terra SG; Mancuso JP; Engel SS; Lauring B
    Diabetes Ther; 2018 Feb; 9(1):253-268. PubMed ID: 29313282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Sitagliptin in Hispanic/Latino Patients with Type 2 Diabetes: A Pooled Analysis from Ten Randomized, Placebo-Controlled Phase 3 Clinical Trials.
    Raji A; Long J; Lam RLH; O'Neill EA; Engel SS
    Diabetes Ther; 2018 Aug; 9(4):1581-1589. PubMed ID: 29936573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
    Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus.
    Cho HA; Jung YL; Lee YH; Lee YC; Lee JE; Lee SJ; Jeong SJ; Kim CH
    J Obes Metab Syndr; 2017 Jun; 26(2):107-113. PubMed ID: 31089504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.